Abstract
Introduction: early diagnosis and intervention of neonatal necrotizing enterocolitis (NEC) are crucial for improving prognosis. It was to assess the diagnostic and staging value of high-sensitivity C-reactive protein (hs-CRP), white blood cell count (WBC), and interleukin (IL)-6 levels in NEC, and to explore their correlation with disease severity. Materials and Methods: this retrospective study analyzed clinical data from 43 NEC patients in the neonatology department of Northwest Women and Children’s Hospital, designated as the experimental group (EG), and concurrently selected 38 healthy newborns as the control group (CG). Serum hs-CRP, WBC, and IL-6 were measured in both groups. Statistical analyses were performed using SPSS 27.0. Results: hs-CRP, WBC, and IL-6 in NEC patients greatly surpassed those in healthy newborns, and these markers were notably positively correlated with NEC staging (r=0.756, 0.234, 0.901, P<0.05). Combined detection of hs-CRP, WBC, and IL-6 in early NEC diagnosis yielded an AUC of 0.988, with a sensitivity of 93.02% and specificity of 97.37%, all superior to individual detections (P<0.05). Conclusion: hs-CRP, WBC, and IL-6 have important value in diagnosis and assessment of NEC, particularly the combined detection which greatly improves early diagnostic accuracy. Future research should further investigate additional inflammatory markers to optimize diagnostic methods, providing a more comprehensive scientific basis for early clinical intervention and treatment.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.